ArticleClinical epigenetics2025
Hypermethylated USP44 deubiquitinates SENP2: a critical mechanism in esophageal cancer progression and a new target for intervention.
Article in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Relevance of USP44 Expression and DNA Methylation Status in Breast Cancer Cell Lines, Tumor Tissues, and Circulating Tumor DNA.Breast cancer (Dove Medical Press) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundUbiquitin-specific proteases (USPs) play a critical role in the development of various cancers. The study aimed to elucidated the pathogenic molecular mechanisms and analyze its clinical significance in esophageal squamous cell carcinoma (ESCC).
methodsPyrosequencing, RT-qPCR and Western blot were used to detect the promoter DNA methylation level and expression of USP44 in ESCC tissues and cell lines, and the significance of USP44/SENP2 in the progression of ESCC was evaluated by in vitro and in vivo experiments. The regulatory mechanism of USP44 on SENP2 was explored by liquid chromatography-mass spectrometry, co-immunoprecipitation (Co-IP) combined with cycloheximide (CHX) tracking assay and ubiquitination analysis. Finally, 182 ESCC tissues were stained with immunohistochemistry (IHC), and the correlation between USP44 and prognosis was evaluated by Kaplan-Meier survival analysis, Cox regression and Nomogram model.
resultsIn ESCC tumor tissues and cell lines, USP44 is frequently hypermethylated and downregulated. Overexpression of USP44 significantly inhibits ESCC cell invasion and metastasis both in vitro and in vivo. Mechanistically, USP44 interacts with and stabilizes ubiquitin-like modifier (SUMO)-specific peptidase 2 (SENP2) through deubiquitination, thereby inhibiting the progression of ESCC. Knockdown of SENP2 reduced the inhibitory effect of USP44 on ESCC cell migration and invasion. Clinically, low expression of USP44 indicates poor prognosis and is an independent prognostic factor in ESCC patients, as evidenced by Kaplan-Meier curve and cox regression analysis (HR = 0.345, 95% CI 0.227-0.524, p < 0.001). We established a nomogram model with robust predictive power for the 1-, 3-, and 5-year survival of ESCC patients (AUC = 0.849).
conclusionUSP44-SENP2 axis is a pivotal factor in the progression of ESCC, and provides potential therapeutic targets for ESCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.